Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Anti-idiotypic antibodies as molecular mimics of conserved influenza hemagglutinin epitopes.

Created on 15 Sep 2026

Authors

Hiroshi Itou, Kaori Sano, Akira Ainai, Kazushige Otsuki, Toshikazu Inoue, Takuya Hemmi, Hideki Hasegawa, Tadaki Suzuki

Published in

Protein science : a publication of the Protein Society. Volume 35. Issue 10. Pages e70795.

Abstract

Broadly neutralizing antibodies (bNAbs) provide insights for developing universal influenza vaccines through their ability to neutralize diverse viral strains. However, designing antigens that reliably elicit bNAb responses remains challenging due to the difficulty in targeting conserved epitopes with a single antigen. We developed a method using anti-idiotypic antibodies (IDs) to generate antigens that induce cross-reactive antibodies against diverse influenza A and B hemagglutinins. Our approach leverages IDs that mimic the conformational epitopes targeted by bNAbs. Structural analysis reveals conformational similarity between bNAb-ID and bNAb-HA-binding interfaces, providing mechanistic insight into molecular mimicry. These epitope-mimicking IDs function as effective immunogens, inducing highly cross-reactive antibodies. This study demonstrates the feasibility and structural basis of molecular mimicry-based antigen design for targeting conserved conformational epitopes. Although these findings establish proof of concept, vaccine applicability requires further investigation.

PMID:
42742346
Bibliographic data and abstract were imported from PubMed on 15 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 20
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement